Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 8/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20720711 | 0.90 | ACP1 (0.46) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720625 | 0.89 | ACP1 (0.45) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720609 | 0.89 | ACP1 (0.47) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720776 | 0.87 | ACP1 (0.43) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720695 | 0.84 | HRH3 (0.47) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720778 | 0.82 | ACP1 (0.45) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720734 | 0.80 | EHMT2 (0.48) | ACP1 | |
| Formic Acid SCHEMBL19260731 | 0.80 | ACP1 (0.50) | ACP1HRH3CACNA2D1KCNH2ADRA1A | |
| SCHEMBL20720659 | 0.79 | EHMT2 (0.39) | ACP1HRH3CACNA2D1KCNH2SRC | |
| SCHEMBL20720742 | 0.79 | ACP1 (0.45) | ACP1HRH3HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | ACP1 3686/4885HRH3 1038/4885CACNA2D1 1539/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | ACP1 3686/4885HRH3 1038/4885CACNA2D1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.